



# PHARMA MONTHLY

SEPTEMBER 2025

**PROGRESSIVE®**  
Your Progress Our Priority...

[www.progressiveshares.com](http://www.progressiveshares.com) | [f](#) [X](#) [@progressiveshar](#) | [@Research Analyst](#)

Equities | Derivatives | Commodities | Currency | PMS | Depository | Mutual Funds | NBFC | e-Broking



## Key News for the Month

### Company

- Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2ml (0.5mg/mL) single-dose vials
- Zydus launches VaxiFlu™ India's first trivalent influenza vaccine for flu protection
- Zydus ties up with Synthon BV for multiple sclerosis drug launch in the US
- USFDA issues Form 483 with 8 observations to Aurobindo's Telangana unit
- Glenmark initiates multi-nation Phase 3 clinical trial for lung cancer drug
- Closure of USFDA inspection at Zydus' injectable manufacturing plant at Jarod
- AstraZeneca to invest Rs176cr to expand GITC in Chennai
- Cupid announces strategic investment in fragrance brand Mansam
- Biocon inaugurates first manufacturing facility in the US
- Dr. Reddy's inks pact with Johnson & Johnson to acquire vertigo treatment brand
- Apollo Hospitals to acquire 31% stake held by IFC in arm Apollo Health & Lifestyle for Rs1,254cr
- Alembic Pharma's API units get an EIR status from the USFDA
- ZyVet launches first generic treatment for Canine Urinary Incontinence
- Lupin's Nagpur injectable facility ends with 6 observations
- Dr. Reddy's launches novel molecule Tegoprazan in India
- Dr. Reddy's to Macleods start preparing for Ozempic patent expiry
- AstraZeneca's asthma drug fails 'smoker's lung' study
- Aurobindo's WoS has incorporated a new WoS in Malaysia
- Biocon Biologics receives USFDA approval for Bosaya and Aukelso, Denosumab biosimilars
- Natco's Kothur, Hyderabad facility has received an EIR from the USFDA classifying the facility as VAI
- Fermenta Board approves sale of environmental solutions biz to subsidiary
- Fire at subsidiary unit temporarily hits production: Aurobindo Pharma
- Alkem launches breast cancer biosimilar in India
- Pfizer closes in on USD7.3bn takeover of anti-obesity drugmaker Metsera: Report
- Lupin gets tentative nod from USFDA for generic HIV treatment drug

### Industry

- India's drug regulator eyes lighter oversight, more AI to boost efficiency
- GST cut on drugs, medical devices to provide relief to patients: Industry players
- Pharma companies cheer lower drug prices, API tax gap stirs worry
- Indian pharma sector needs price hikes, site and IP transfers to tackle US tariff uncertainty: Report

### Global

- Roche Pharma partners with 10 govt. hospitals to bolster clinical trial capabilities in India
- Novo Nordisk to test weight-loss drugs in broader range of obesity-linked conditions
- Sanofi expands USD35-per-month pricing to all insulin products
- AstraZeneca joins the DTC platform pack, offering up to 70% discounts on Farxiga, Aircupra

## Tentative ANDA Approvals

Company	API	Strengths	Indications	Brand (Company)	Mkt Size
<b>Lupin</b>	Bictegravir, Emtricitabine and Tenofovir Alafenamide Tablets	50/200/25mg	Indicated for the treatment of HIV infection in adults and pediatric patients	Biktarvy Tablets (Gilead Sciences Inc.)	USD16,237mn (annual sales Jul'25)

Source: Media Reports and Company Press Releases

## Final ANDA Approvals

Company	API	Strengths	Indications	Brand (Company)	Mkt Size
<b>Caplin Point</b>	Milrinone Lactate in 5% Dextrose Injection	20mg/100mL (0.2mg/mL) and 40mg/200mL (0.2mg/mL) Single dose infusion bags	Indicated for the short-term intravenous treatment of patients with acute decompensated heart failure	Primacor (Sanofi Aventis US LLC.)	USD11mn (annual sales Jul'25)
<b>Alembic Pharma</b>	Phytonadione Injectable Emulsion	1mg/0.5mL Single dose prefilled syringe	Indicated for the treatment of hypoprothrombinemia due to vitamin K deficiency	Phytonadione Injectable Emulsion (International Medication Systems Ltd)	USD44mn
<b>Lupin</b>	Lenalidomide Capsules	2.5/5/10/15/20/25mg	Indicated for the treatment of adult patients with Multiple Myeloma (MM)	Revlimid (Bristol-Myers Squibb Company)	USD7511mn (annual sales Jul'25)
<b>Alembic Pharma</b>	Paroxetine ER Tablets	25/37.5mg	Indicated for the treatment of major depressive disorder	Paxil CR ER Tablets (Apotex Inc.)	-

Source: Media Reports and Company Press Releases

BSE Health Care Index Price Performance				
Companies	Price	Change		
		1 M	6 M	12 M
Aarti Drugs Ltd	486	2.7%	41.5%	-5.3%
Abbott India Ltd	29282	-8.7%	-3.4%	0.4%
Advanced Enzyme Technologies Ltd	325	-3.9%	13.3%	-35.3%
Ajanta Pharma Ltd	2407	-1.8%	-8.0%	-24.8%
Alembic Pharmaceuticals Ltd	900	-4.4%	0.3%	-25.3%
Alkem Laboratories Ltd	5422	2.3%	12.2%	-10.5%
Acutaas Chemicals Ltd	1319	-6.7%	-47.8%	-24.3%
Anuh Pharma Ltd	84	-4.0%	-45.4%	-59.6%
Apollo Hospitals Enterprise Ltd	7411	-3.5%	11.8%	3.0%
Artemis Medicare Services Ltd	234	3.4%	-14.0%	-17.7%
Aster DM Healthcare Ltd	627	3.6%	30.6%	51.1%
AstraZeneca Pharma India	9118	4.2%	7.0%	14.5%
Aurobindo Pharma Ltd	1084	5.7%	-4.5%	-25.8%
Alivus Lifesciences Ltd	929	-0.8%	-10.1%	-12.2%
Bajaj Healthcare Ltd	488	14.9%	-27.3%	29.7%
Biocon Ltd	341	-3.32%	0.5%	-6.1%
Bliss GVS Pharma Ltd	153	-3.4%	28.1%	16.2%
Caplin Point Laboratories Ltd	1968	-6.7%	-0.5%	3.7%
Cipla Ltd	1502	-5.4%	3.9%	-9.2%
Cohance Lifesciences Ltd	879	-2.6%	-18.2%	-25.1%
Dishman Carbogen Amics Ltd	276	5.2%	25.1%	53.6%
Divi's Laboratories Ltd	5688	-6.6%	2.5%	4.4%
Dr. Reddy's Laboratories Ltd	1224	-4.4%	6.2%	-9.5%
Eris Lifesciences Ltd	1589	-10.7%	14.2%	19.5%
FDC Ltd	442	-3.2%	9.9%	-18.0%
Fermenta Biotech Ltd	312	-3.3%	9.3%	3.0%
Fortis Healthcare Ltd	970	4.9%	40.9%	57.8%
Gland Pharma Ltd	1993	6.7%	28.2%	11.0%
GSK Pharmaceuticals Ltd	2657	-5.3%	-4.9%	-3.6%
Glenmark Pharmaceuticals Ltd	1953	1.3%	29.4%	16.7%
Global Health Ltd	1313	-5.9%	6.7%	27.8%
Granules India Ltd	516	0.2%	6.8%	-7.5%
Gufic Biosciences Ltd	352	-2.9%	4.5%	-8.6%
Gujarat Themis Biosyn Ltd	397	3.3%	46.1%	7.8%
HealthCare Global Enterprises Ltd	647	-3.6%	22.0%	54.8%
Hester Biosciences Ltd	1893	-7.1%	26.9%	-22.6%
Hikal Ltd	252	-1.8%	-37.3%	-32.3%
Indoco Remedies Ltd	293	9.6%	19.4%	-18.5%
Indraprastha Medical Corp. Ltd	445	-0.6%	13.5%	4.2%
IOL Chemicals and Pharma Ltd	102	10.0%	60.8%	-78.4%
IPCA Laboratories Ltd	1341	-1.8%	-3.7%	-10.4%
J.B.Chemicals & Pharmaceuticals Ltd	1708	-1.0%	10.2%	-8.9%
Jagsonpal Pharmaceuticals Ltd	219	-8.5%	1.0%	-47.7%
Jubilant Pharmova Sciences Ltd	1079	3.8%	18.0%	-6.4%
KMC Speciality Hospitals Ltd	66	-2.0%	6.6%	-20.4%
KIMS Ltd	700	-3.7%	13.4%	25.6%
Kopran Ltd	174	9.7%	-6.8%	-47.4%
Kovai Medical Center & Hospital Ltd	6133	-2.6%	18.0%	16.4%
Krsnaa Diagnostics Ltd	757	-5.0%	-4.8%	-10.3%

Source: BSE website; All prices are as on 30th September, 2025


BSE Health Care Index Price Performance				
Companies	Price	Change		
		1 M	6 M	12 M
Lal PathLabs Ltd	3113	-4.8%	29.5%	-5.7%
Laurus Labs Ltd	842	-2.1%	40.7%	81.9%
Lincoln Pharmaceuticals Ltd	532	-1.9%	-3.4%	-20.5%
Lupin Ltd	1910	0.6%	-2.4%	-12.8%
Marksans Pharma Ltd	165	-1.7%	-25.6%	-44.6%
Max Healthcare Institute Ltd	1116	-5.4%	3.0%	13.2%
Medicamen Biotech Ltd	295	-14.8%	-40.3%	-48.1%
Metropolis Healthcare Ltd	2048	-4.7%	34.1%	-6.5%
Morepen Laboratories Ltd	48	-0.5%	-2.9%	-44.0%
Natco Pharma Ltd	796	-8.0%	-1.1%	-44.0%
Nectar Lifesciences Ltd	15	2.2%	-39.9%	-63.8%
Neuland Laboratories Ltd	14622	9.1%	27.4%	18.0%
NGL Fine-Chem Ltd	1419	-2.2%	24.8%	-29.6%
Narayana Hrudayalaya Ltd	1734	-2.8%	3.4%	38.6%
Novartis India Ltd	875	-6.2%	8.4%	-21.8%
Nureca Ltd	228	-5.6%	3.3%	-37.4%
Panacea Biotech Ltd	406	-2.5%	-10.0%	35.0%
Pfizer Ltd (India)	5030	-2.1%	24.6%	-12.0%
Piramal Pharma Ltd	191	1.7%	-15.4%	-16.6%
Procter & Gamble Health Ltd	6311	0.0%	22.5%	16.3%
Poly Medicure Ltd	1945	-6.1%	-9.6%	-16.0%
RPG Life Sciences Ltd	2227	-4.6%	-1.3%	-5.4%
Rainbow Children's Medicare Ltd	1356	-9.6%	-0.9%	-3.0%
Sanofi India Ltd	4651	-9.1%	-20.3%	-34.1%
Sastasundar Ventures Ltd	305	12.2%	20.2%	1.7%
Sequent Scientific Ltd	187	9.5%	37.4%	-19.8%
Shalby Ltd	265	34.9%	31.4%	-5.4%
Shilpa Medicare Ltd	754	-11.1%	14.7%	-7.3%
Sigachi Industries Ltd	39	19.9%	4.3%	-29.9%
SMS Pharmaceuticals Ltd	246	3.4%	12.5%	-30.0%
Solara Active Pharma Sciences Ltd	604	-4.8%	18.1%	-24.6%
SPARC Ltd	129	-9.0%	-11.7%	-40.1%
Strides Pharma Science Ltd	825	-8.0%	23.4%	-41.1%
Sun Pharmaceutical Industries Ltd	1595.0	2.0%	-6.01%	-17.2%
Supriya Lifescience Ltd	728.6	9.9%	-0.5%	29.4%
Suven Life Sciences Ltd	203	-3.0%	66.7%	44.6%
Snycom Formulations (India) Ltd	16	-3.9%	-5.7%	-26.0%
Syngene International Ltd	623	-1.8%	-13.2%	-30.6%
Take Solutions Ltd	11	8.6%	61.9%	-45.6%
Tarsons Products Ltd	305	-5.2%	-13.5%	-31.3%
Thyrocare Technologies Ltd	1160	-10.0%	60.9%	42.9%
Torrent Pharmaceuticals Ltd	3601	0.5%	13.2%	5.9%
Themis Medicare Ltd	135	34.4%	-9.4%	-50.6%
Unichem Laboratories Ltd	462	-8.0%	-33.8%	-29.8%
Venus Remedies Ltd	440	-4.5%	40.4%	30.3%
Vijaya Diagnostic Centre Ltd	999	-4.1%	2.8%	3.5%
Vimta Labs Ltd	706	7.7%	-27.0%	30.1%
Windlas Biotech Ltd	906	-9.7%	-11.0%	8.4%
Wockhardt Ltd	1514	6.9%	4.9%	54.2%
Zydus Lifesciences Ltd	982	-0.9%	11.9%	-8.1%

Source: BSE website; All prices are as on 30th September, 2025



NIFTY PHARMA COMPANIES					
Company	Price (Rs)	Mcap (Rs mn)	Change		
			1 M	6 M	12 M
Abbott India Ltd	29282	622229	-8.7%	-3.4%	0.4%
Alkem Laboratories Ltd	5422	648305	2.3%	12.2%	-10.5%
Aurobindo Pharma Ltd	1084	629502	5.7%	-4.5%	-25.8%
Ajanta Pharma Ltd	2407	300682	-1.8%	-8.0%	-24.8%
Biocon Ltd	341	455704	-3.3%	0.5%	-6.1%
Cipla Ltd	1502	1212984	-5.4%	3.9%	-9.2%
Divi's Laboratories Ltd	5688	1509853	-6.6%	2.5%	4.4%
Dr. Reddy's Laboratories Ltd	1224	1021278	-4.4%	6.2%	-9.5%
Gland Pharma Ltd	1993	328393	6.7%	28.2%	11.0%
Glenmark Pharmaceuticals Ltd	1953	551054	1.3%	29.4%	16.7%
Granules India Ltd	516	125201	0.2%	6.8%	-7.5%
Ipca Laboratories Ltd	1341	340306	-1.8%	-3.7%	-10.4%
J.B. Chemicals & Pharmaceuticals Ltd	1708	266533	-1.0%	10.2%	-8.9%
Laurus Labs Ltd	842	454506	-2.1%	40.7%	81.9%
Lupin Ltd	1910	872396	0.6%	-2.4%	-12.8%
Mankind Pharma Ltd	2290	945169	-6.9%	-5.7%	11.6%
Natco Pharma Ltd	796	142491	-8.0%	-1.1%	-44.0%
Sun Pharmaceutical Industries Ltd	1595	3826819	2.0%	-6.01%	-17.2%
Torrent Pharmaceuticals Ltd	3601	1218624	0.5%	13.2%	5.9%
Zydus Lifesciences Ltd	982	987820	-0.9%	11.9%	-8.1%

Source: NSE website, Company Research; All prices are as on 30th September, 2025



Source: NSE website

#### DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

#### Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

#### Registered Office Address:

Progressive Share Brokers Pvt. Ltd,  
122-124, Laxmi Plaza, Laxmi Indl Estate,  
New Link Rd, Andheri West,  
Mumbai—400053, Maharashtra  
www.progressiveshares.com | Contact No.:022-40777500.

#### Compliance Officer:

Ms. Neha Oza,  
Email: compliance@progressiveshares.com,  
Contact No.:022-40777500.

#### Grievance Officer:

Email: grievancecell@progressiveshares.com